Scholarlink

Objective <p>To investigate the feasibility of early dynamic 2-[<sup>18</sup>F]-fluoro-2-deoxy-<span>d</span>-glucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) imaging in predicting epidermal growth factor receptor (EGFR) and tumor protein 53 (TP53) mutation status in lung adenocarcinoma (AC).</p> Methods <p>In total, 81 patients with lung nodules underwent early dynamic PET (10&#xa0;min after injection) and late static PET (60&#xa0;min after injection), and 41 (18 male, 23 female; mean age 64 ± 10&#xa0;years) with confirmed AC were included in the final analysis. Dynamic images were reconstructed into 25 frames, and time-to-activity curves were generated. An irreversible two-tissue compartment model was used to derive kinetic parameters (K<sub>1,</sub> k<sub>2</sub>, k<sub>3</sub>, Ki, and MR<sub>FDG</sub>). EGFR and TP53 mutation statuses were determined via histological analysis. Statistical tests, including the Wilcoxon rank-sum test, Kruskal–Wallis H test, and Spearman’s correlation, were used to assess differences and associations among groups. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the predictive performance.</p> Results <p>In patients with AC, k<sub>3</sub>, Ki, and MR<sub>FDG</sub> were strongly correlated with SUV<sub>max</sub> (r = 0.821, 0.862, and 0.778, respectively; all <i>P</i> &lt; 0.001). SUV<sub>max</sub>, k<sub>3</sub>, Ki, and MR<sub>FDG</sub> differed significantly between patients with AC and SCC, as well as across TNM and pathological stage subgroups (<i>P</i> &lt; 0.05). SUV<sub>max</sub> and k<sub>3</sub> were significantly lower in the EGFR-positive group, while Ki was higher in the TP53-positive group (<i>P</i> &lt; 0.05). AUCs for predicting EGFR mutation were 0.718 (SUV<sub>max</sub>) and 0.776 (k<sub>3</sub>), and 0.703 (Ki) for TP53 mutation.</p> Conclusions <p>Early dynamic <sup>18</sup>F-FDG PET/CT may serve as a valuable non-invasive tool for predicting EGFR and TP53 mutation status in AC, for screening patients for targeted therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Feasibility of Early Dynamic 18F-FDG PET/CT Imaging for Predicting EGFR and TP53 Mutations in Lung Adenocarcinoma

  • 期刊论文

  • 发表日期：

    2025年11月14日

查看全文
  • Ying Zhang,
  • Guobing Liu,
  • Yingying Guan,
  • Beilei Li,
  • Yiqiu Zhang

摘要

Objective

To investigate the feasibility of early dynamic 2-[18F]-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) imaging in predicting epidermal growth factor receptor (EGFR) and tumor protein 53 (TP53) mutation status in lung adenocarcinoma (AC).

Methods

In total, 81 patients with lung nodules underwent early dynamic PET (10 min after injection) and late static PET (60 min after injection), and 41 (18 male, 23 female; mean age 64 ± 10 years) with confirmed AC were included in the final analysis. Dynamic images were reconstructed into 25 frames, and time-to-activity curves were generated. An irreversible two-tissue compartment model was used to derive kinetic parameters (K1, k2, k3, Ki, and MRFDG). EGFR and TP53 mutation statuses were determined via histological analysis. Statistical tests, including the Wilcoxon rank-sum test, Kruskal–Wallis H test, and Spearman’s correlation, were used to assess differences and associations among groups. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the predictive performance.

Results

In patients with AC, k3, Ki, and MRFDG were strongly correlated with SUVmax (r = 0.821, 0.862, and 0.778, respectively; all P < 0.001). SUVmax, k3, Ki, and MRFDG differed significantly between patients with AC and SCC, as well as across TNM and pathological stage subgroups (P < 0.05). SUVmax and k3 were significantly lower in the EGFR-positive group, while Ki was higher in the TP53-positive group (P < 0.05). AUCs for predicting EGFR mutation were 0.718 (SUVmax) and 0.776 (k3), and 0.703 (Ki) for TP53 mutation.

Conclusions

Early dynamic 18F-FDG PET/CT may serve as a valuable non-invasive tool for predicting EGFR and TP53 mutation status in AC, for screening patients for targeted therapy.